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W 
e  have come a long way since the identification of 
the first human tumor antigen recognized by autol- 
ogous CTL. This report provides a brief appraisal of these 
antigens  and  their  potential  for  cancer  immunotherapy. 
Our comments will be restricted to nonviral antigens. 
The initial work carried out on mouse tumors revealed 
two possible mechanisms for generating new antigens that 
might be suflficiendy tumor-specific to be of relevance to 
immunotherapy.  The  first  mechanism  involved  a  point 
mutation, and the second involved the transcriptional acti- 
vation ofa gene not expressed in normal tissues (1-3). Sub- 
sequent  work on mouse tumors provided two interesting 
examples of tumor antigens resulting from point mutations 
(4, 5). 
Tumor-specific Shared Antigens.  Three  families  of genes 
that appear to code for highly specific tumor antigens have 
been  identified  so  far,  namely,  the  MAGE,  BAGE,  and 
GAGE genes  (6-9).  These genes are frequently expressed 
in a wide range of tumor types such as melanoma, lung car- 
cinoma, sarcoma, and bladder carcinoma, but very rarely in 
other tumor types such as brain  tumors,  renal carcinoma, 
and leukemia  (7,  10-12).  The  only normal tissues  where 
expression of these genes has been observed are testis and 
placenta (7).  Starting from CTL clones obtained by stimu- 
lating lymphocytes with an autologous melanoma cell line, 
six antigens encoded by MAGE-1, MAGE-3,  BAGE, and 
GAGE have been identified (8, 9, 13-15). For these six an- 
tigens,  both  the  presenting  HLA molecule  and  the  anti- 
genic peptide have been completely defined. Remarkably, 
all  the  relevant  CTL were  derived  from the  same  mela- 
noma patient, a patient with metastatic disease who enjoyed 
an extraordinarily favorable chnical course. Blood samples 
from several patients with a tumor expressing some or all of 
these genes were tested,  and no such CTL were obtained 
by stimulating the lymphocytes with autologous tumor cells. 
More  than  60%  of Caucasian  melanoma patients  bear 
one of the presently defined antigens encoded by MAGE, 
BAGE,  and  GAGE.  For  other  cancers  such  as  head  and 
neck  tumors  and  bladder  cancer,  the  frequencies  range 
from 40%  to 28%.  For several reasons,  it appears increas- 
ingly unlikely that immunization of patients against one of 
these  antigens  will  cause  harmful  immunological  side  ef- 
fects caused by the expression of the relevant gene in the 
testis.  First,  this  expression  appears to  occur in  germline 
cells, more precisely spermatocytes and spermatogonia (16). 
A similar observation has been made with the mouse equiv- 
alent of a MAGE gene by in situ hybridization  (17).  Be- 
cause  these  germline  cells  do  not  express  classical  MHC 
class I molecules, gene expression should not result in anti- 
gen expression (18).  These conclusions are further strength- 
ened by immunization studies carried out with mouse tu- 
mor antigen P815A, which is encoded by a gene that is also 
expressed only in the testis.  After immunization with P815 
tumor cells,  which carry this antigen, male mice produced 
a strong CTL response. No inflammation of the testis  was 
observed in the following months, and the fertihty of these 
mice was normal (Uyttenhove, C., manuscript in prepara- 
tion). 
A  new mode of origin for antigens that are also tumor- 
specific shared antigens is described in this issue (19).  Here, 
it seems that a gene that is ubiquitously expressed, namely, 
N-acetyl-glucosaminyltransferase V, contains an intron that 
appears to carry near its end a promoter that is activated only 
in melanoma cells. This atypical activation occurs in >50% 
of melanomas. This produces a message containing a new 
open reading frame, which codes for the antigenic peptide 
in its intronic part. 
Some CTL directed against breast, ovarian, and pancre- 
atic  carcinomas recognize  an  epitope  of mucin,  a  surface 
protein composed of multiple tandem repeats of 20 amino 
acids  (20-23).  Whereas  in  normal  cells  mucin  is  heavily 
glycosylated, in  these  tumors  the  peptide  repeats  are  un- 
masked by underglycosylation,  resulting in  CTL recogni- 
tion. Remarkably, this recognition, which depends on the 
presence of multiple repeats, occurs in the absence of HLA 
restriction.  The presence  of this  epitope was recently re- 
ported  on  myeloma cells,  and  mucin-specific  CTL were 
isolated from the blood of a myeloma patient (24).  These 
mucin antigens appear to be very specific for tumor cells, 
and the lack of HLA restriction should facilitate therapeutic 
vaccination trials. 
Differentiation Antigens.  The  observation  that  autolo- 
gnus  CTL can be generated readily against differentiation 
antigens  present  on normal melanocytes as  well  as  mela- 
noma  cells  was  unexpected.  Four  genes  encoding  mela- 
noma differentiation antigens have been identified:  tyrosi- 
nase, Melan-A/Mart-1, gpl00, and gp75  (25-30). Most of 
the identified antigenic peptides are presented by HLA-A2, 
but  other  HLA-peptide  combinations  have  been  found 
(29-38). One tyrosinase peptide is presented by HLA-DR4 
to CD4 T  cells (34). 
The pattern of CTL precursors directed against these dif- 
725  J. Exp. Med. ￿9  The Rockefeller University Press ￿9 0022-1007/96/03/725/05  $2.00 
Volume 183  March 1996 725-729 ferentiation antigens appears to be very different from that 
observed with the MAGE-like antigens. Here, most mela- 
noma patients have CTL precursors that can be readily re- 
stimulated  in vitro with  autologous  tumor  cells  (33,  39). 
TIL populations  also  contain these  CTL (32).  How these 
findings affect the immunotherapy potential of these anti- 
gens is unclear. The fact that many patients carry CTL pre- 
cursors against these antigens implies that active immuniza- 
tion resulting in an increase in the number of these  CTL 
should be possible. On the other hand, the fact that many 
of these patients have progressive disease suggests that these 
CTL are not very effective. 
There is concern for the potential side effects of active or 
passive immunization against melanoma differentiation an- 
tigens. Not so much for the skin, where vitiligo caused by 
the destruction ofmelanocytes might occur, but for the uvea 
where melanocytes are present in the  choroid layer. Viti- 
ligo, however, has been associated with good prognoses in 
melanoma and also with adoptive transfer of TILs, without 
noticeable eye lesions (35, 37, 40, 41).  Carefully devised im- 
munotherapy trials  based on these antigens therefore seem 
permissible. 
Antigens Specific  for Individual Tumors.  Point  mutations 
also generate antigens recognized on melanoma by autolo- 
gous CTL. As was seen with the mouse antigens induced 
by mutagens, the mutations are located in the region cod- 
ing  for the  antigenic  peptide,  enabling it  to  bind  to  the 
MHC molecule or generating a new epitope. A very inter- 
esting example is the point mutation of cyclin-dependent 
kinase 4  (42),  which prevents this protein from binding to 
p16, thereby increasing the probabihty of its binding to the 
cyclin molecule and phosphorylating P,b,  so that the E2F 
transcription factor is released and activates genes required 
for entry into the S phase of the cell cycle. This is clearly a 
mutation that is both antigenic and oncogenic. In addition 
to the melanoma tumor where the antigen was first identi- 
fied,  1  out  of 28  melanomas that were  tested carried this 
mutation, confirming the oncogenic potential of this muta- 
tion.  The  amino  acid  change  generated by this  mutation 
enables  the  peptide  to  bind  to  the  HLA-A2  presenting 
molecule.  Another  interesting  point  mutation  produces  a 
new  antigenic  peptide which,  remarkably, is  partially en- 
coded by the 5' end of an intron (43).  In this instance, the 
mutation generates a new epitope. Finally, this issue  con- 
tains a report describing an antigenic peptide produced by a 
mutation in the 13-catenin  gene, which codes for a cell sur- 
face  adhesion  molecule.  This mutation  creates an  anchor 
residue enabling the peptide to bind to HLA-A24 (44). 
The antigens generated by point mutations ought to be 
absolutely specific for the tumor cells, and the CTL precur- 
sors directed against these antigens should not have under- 
gone any of the depletion or anergy that accompany natu- 
ral tolerance. On the other hand,  they are expected to be 
unique  for an individual  tumor or restricted to very few. 
This should make it difficult to develop cancer therapeutic 
vaccines based on these antigens.  But one should  not ex- 
clude  the  possibihty that  technological  progress may one 
day make the  identification  of such  antigens  so  easy that 
strictly individual immunogens will become a realistic pos- 
sibility. 
Ubiquitous Antigens.  Some antigens that are recognized 
by autologous CTL stimulated in vitro with tumor cells ap- 
pear  to  be  encoded  by  genes  that  are  ubiquitously  ex- 
pressed (45).  We have identified more than six such genes, 
some of which show a significant degree of overexpression 
in the tumor cells  (Brichard,  V.,  P.G.  Couhe,  and P.  van 
der  Bruggen,  personal  communications).  Unless  these 
genes show a much higher degree of expression in tumor 
cells, as is observed with the HER-2/neu gene (46-49), one 
does not see how these antigens could be used for immu- 
notherapy. 
"Reverse Immunology."  Two antigens encoded by MAGE 
genes  were  identified  by  "reverse immunology:" starting 
from the sequence of the putative protein, candidate pep- 
tide sequences carrying consensus anchor motives for a cer- 
tain HLA were located (50).  These peptides were synthe- 
sized and some of them were found to effectively bind to 
the HLA molecule. Peptide-pulsed cells were then used to 
stimulate  lymphocytes  obtained  from  normal  individuals 
carrying the  relevant HLA-type, and CTL were  obtained 
that lysed not  only peptide-pulsed  cells  but  also  cells  ex- 
pressing the  appropriate MAGE  gene  (51-53).  In several 
instances, however, we have obtained CTL that recognize 
peptide-pulsed cells, but not the cells that express the rele- 
vant genes. 
On the basis of the observation that a point mutation can 
generate new antigens  (1,  2),  this  approach has also been 
used to identify antigens encoded by mutated oncogenes. 
CD8 §  clones from a  colon  carcinoma patient,  stimulated 
with a 25-amino acid mutated ras peptide, were capable of 
lysing a colon carcinoma line expressing a ras gene carrying 
this  mutation  (54).  Mouse  CD8 +  CTL,  obtained  after in 
vivo immunization with a mutated p53 peptide, were like- 
wise  capable  of lysing  H-2-matched  cells  expressing  the 
mutated p53 gene (55).  Here again, after stimulation with a 
mutated  peptide,  several groups  have  obtained  CTL  that 
recognize only peptide-pulsed cells (56-59). 
Will the antigens identified by direct immunology (i.e., 
by CTL resulting from tumor  cell  stimulation  of autolo- 
gnus lymphocytes) prove to be superior for immunother- 
apy to  those  identified  by reverse  immunology involving 
stimulation with peptide-pulsed cells?  We  do  not believe 
that this possibility can be ignored,  since the lymphocytes 
that were stimulated with autologous tumor cells may have 
preferentially responded to the first group of antigens, be- 
cause  these  antigens  are better able  to  induce  a  CTL re- 
sponse, either because they are more abundant or because 
CTL with receptors of high affinity exist against them. But 
only chnical trials  will provide definitive evidence regard- 
ing the usefulness of the two types of antigens. 
Some of the tumor antigens that we have mentioned are 
in early stages of clinical study. There is little doubt that the 
coming years will witness a large number of clinical trials 
involving peptides, proteins, and recombinant defective vi- 
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patients (60), and that the careful study of the lymphocytes 
and  the  tumor  cells of these  patients ~  produce  a  rich 
harvest of additional antigens and a better understanding of 
what constitutes an effective antitumor response. 
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